T
Timothy C. Rodell
Publications - 5
Citations - 4140
Timothy C. Rodell is an academic researcher. The author has contributed to research in topics: Placebo-controlled study & Survival analysis. The author has an hindex of 4, co-authored 5 publications receiving 4012 citations.
Papers
More filters
Journal ArticleDOI
Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
Roger C. Bone,Robert A. Balk,F. B. Cerra,R. P. Dellinger,A. M. Fein,William A. Knaus,Roland M. H. Schein,W. J. Sibbald,WA Knous,J. H. Abrams,G. R. Bernard,JW Biondi,JE Calvin,R Demling,PJ Fahey,CJ Fisher,C Franklin,KJ Gorelick,MA Kelley,DG Maki,JC Marshall,WW Merrill,JP Pribble,EC Rackow,Timothy C. Rodell,JN Sheagren,Michael R. Silver,C. L. Sprung,Richard C. Straube,MJ Tobin,GM Trenholme,DP Wagner,CD Webb,JC Wherry,HP Wiedemann,CH Wortel,M. Kylänpää-Bäck +36 more
Journal ArticleDOI
Treatment of Severe Systemic Inflammatory Response Syndrome and Sepsis With a Novel Bradykinin Antagonist, Deltibant (CP-0127): Results of a Randomized, Double-blind, Placebo-Controlled Trial
Alan M. Fein,Gordon R. Bernard,Gerard J. Criner,Eugene Fletcher,James T. Good,William A. Knaus,Howard Levy,George M. Matuschak,Harvey M. Shanies,Robert W. Taylor,Timothy C. Rodell +10 more
TL;DR: Deltibant may have some effect on survival in patients with SIRS and gram-negative sepsis; however, additional studies would be required to prove this.
Journal ArticleDOI
Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group.
Alan M. Fein,Gordon R. Bernard,Gerard J. Criner,Eugene Fletcher,James T. Good,William A. Knaus,Howard Levy,George M. Matuschak,Harvey M. Shanies,Robert W. Taylor,Timothy C. Rodell +10 more
TL;DR: Deltibant may have some effect on survival in patients with SIRS and gram-negative sepsis; however, additional studies would be required to prove this.